• “常青藤爸爸”一年盈利5000万秘方:靠质量和流量 2019-05-20
  • 企业服务行业跨越式发展 2018年神州顺利办聚焦企业人、财、物 2019-05-20
  • 长租公寓产品趋于多元化 2019-05-20
  • 青海两个光伏发电应用领跑基地 正式开工 2019-05-19
  • 2018年前5个月日照新增市场主体19604户 2019-05-19
  • 2015台湾年终策划:两岸,这一年 2019-05-19
  • 在现时代,无论中国还是西方发达国家都是社会财富公有制和私有制并存的社会,由于仍旧存在社会财富私有制,所以必然存在贫富差别,离开私有制来谈“贫”和“富”... 2019-05-18
  • 上海合作组织成员国领导人共同会见记者习近平作为主席国元首发表讲话 2019-05-18
  • 中国这次强硬反击,传递了四个意味深长的信号! 2019-05-17
  • 【理上网来喜迎十九大】姚树洁:世界看好中国的未来 2019-05-17
  • 花3000吃顿饭不如跟“九星米其林大厨”学道菜 2019-05-16
  • 懵!身前3米没人逼 博格巴传球给了对手 2019-05-16
  • 欧洲为何插手南海? 俄媒:因为他们弱小 2019-05-15
  • 抢占公共交通支付场景 腾讯与上海地铁达成战略合作 2019-05-15
  • “日啖荔枝三百颗”:千万别,大量进食会引发低血糖 2019-05-14
  • About Us

    Shanghai Shyndec Pharmaceutical Co.,Ltd,

    Shanghai Shyndec Pharmaceutical Co.,Ltd, which was established in 1996, is a high-tech enterprise in the pharmaceutical industry which is specialized in manufacturing new drug preparation products and founded by academician of Chinese Academy of Engineering. It was listed on Shanghai stock exchange on June 16, 2004 (stock code: 600420, stock abbreviation:现代制药). In April 2010, it entered China National Pharmaceutical Group Corporation(SINOPHARM).

    In 2016-2017, according to the integration strategy ofSINOPHARM, Shanghai Shyndec Pharmaceutical Co.,Ltd positioned itself as a pharmaceutical industry platform of SINOPHARM, have actively promoted major asset restructuring matters. The main business of the "new Shyndec " wholly-owned or holding subsidiary after the reorganization has achieved nearly 10 billion level of revenue, total profit has exceeded 1 billion yuan, and the number of enterprise members has reached 30, among which 17 are secondary enterprises, 13 are tertiary and four-level enterprises.

    After the reorganization, the "New Shyndec" has integrated into many high-quality industrial product lines and enterprise assets of China National Pharmaceutical Group to create a more centralized resource allocation and a clearer main business market. Focusing on the "anti-infection, cardiovascular and cerebrovascular, anti-tumor, leptin drugs, metabolism and endocrine" five areas then has formed and strengthened the "5 + X" industrial chain system with the modern characteristics and core competitiveness of Chinese medicine. The product structure of the company will be richer, the R&D strength will be further strengthened, and the market position of the enterprise has been improved by leaps and bounds.

    For a year, Shanghai Shyndec Pharmaceutical Co.,Ltd has been guided by "big reorganization, large integration, great amalgamation and fully development". Through the three main paths of " big reorganization of institutional framework, great amalgamation of ideology and culture, great integration of personnel assets" to achieve the development goal of large-scale integration of the group chemical pharmaceutical industry and strive to create a platform of chemical pharmaceutical industry under the guidance of innovation.

    • Stock Code

      600420

    • Stock Abbreviation

      现代制药

    • Company Address:

      Building 1, No. 1320, west Beijing road, Shanghai

    Organizational Structure

  • “常青藤爸爸”一年盈利5000万秘方:靠质量和流量 2019-05-20
  • 企业服务行业跨越式发展 2018年神州顺利办聚焦企业人、财、物 2019-05-20
  • 长租公寓产品趋于多元化 2019-05-20
  • 青海两个光伏发电应用领跑基地 正式开工 2019-05-19
  • 2018年前5个月日照新增市场主体19604户 2019-05-19
  • 2015台湾年终策划:两岸,这一年 2019-05-19
  • 在现时代,无论中国还是西方发达国家都是社会财富公有制和私有制并存的社会,由于仍旧存在社会财富私有制,所以必然存在贫富差别,离开私有制来谈“贫”和“富”... 2019-05-18
  • 上海合作组织成员国领导人共同会见记者习近平作为主席国元首发表讲话 2019-05-18
  • 中国这次强硬反击,传递了四个意味深长的信号! 2019-05-17
  • 【理上网来喜迎十九大】姚树洁:世界看好中国的未来 2019-05-17
  • 花3000吃顿饭不如跟“九星米其林大厨”学道菜 2019-05-16
  • 懵!身前3米没人逼 博格巴传球给了对手 2019-05-16
  • 欧洲为何插手南海? 俄媒:因为他们弱小 2019-05-15
  • 抢占公共交通支付场景 腾讯与上海地铁达成战略合作 2019-05-15
  • “日啖荔枝三百颗”:千万别,大量进食会引发低血糖 2019-05-14